Fewer than ten new brands have launched in the highly generic and crowded Parkinson’s disease (PD) therapy market during the past two decades, but PD’s large and growing elderly population and high polypharmacy rates already impose a moderate burden on U.S. MCOs’ Medicare Advantage Plans, according to DRG research. A wave of new premium-priced brands entering the U.S. market is poised to alter the PD treatment paradigm and impose an even heavier burden on Medicare plans, and with an aging population and surging U.S. healthcare costs, payers have become particularly sensitive to the cost of drugs and medical care. Understanding the impact this payer pressure has on the prescribing of current PD therapies and the market access outlook for emerging therapies is crucial for developers of new and current PD therapeutics facing an increasingly complex market. 


Related Reports

Parkinson's Disease - Landscape & Forecast - Disease Landscape & Forecast

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more a...

View Details

Parkinson's Disease - Unmet Need - Detailed, Expanded Analysis: Psychosis In PD (US/FR/DEU/UK)

Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms. Surveyed neurologists estimate that 20% of their PD patie...

View Details

Parkinson's Disease | Disease Landscape and Forecast | G7 | 2019

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND0612, IPX203); two new re...

View Details